REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE
Clinical trials for REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that returned or didn't respond to prior therapy. First, patients receive tafasitamab (an antibody that targets cancer cells) plus lenalidomide (a drug that helps the immune system fight cancer). Then, th…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 17, 2026 07:39 UTC
-
New drug combo may bridge more patients to lifesaving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help control aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to keep the disease in check so more patients can qualify for and rec…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:53 UTC